UCB S.A.
UCB
Classement en actions
#494
UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in... UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio includes Cimzia, targeting inflammatory TNF-mediated conditions such as Crohn's disease, various forms of spondyloarthritis, rheumatoid arthritis, and psoriasis. For epilepsy management, UCB offers Vimpat, Keppra, and Briviact, along with Nayzilam, an intranasal rescue treatment for seizure clusters. Neupro is available for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Other key products include Evenity for osteoporosis in postmenopausal women, and BIMZELX, which treats psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. The company also provides dapirolizumab pegol for systemic lupus erythematosus. UCB's robust development pipeline features candidates like rozanolixizumab, aimed at myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its proprietary drug development, UCB also conducts contract manufacturing. The company engages in significant collaborations with entities such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. UCB's global footprint extends across numerous countries, including the United States, Japan, China, Belgium, and a broad presence throughout Europe, encompassing Germany, Spain, France, Italy, the United Kingdom, and Ireland.
Prix de l'action
$258.70
Dernière synchronisation: 2026-10-20
Capitalisation boursière
$49.32B
Changement (1 jour)
6.29%
Changement (1 an)
-12.78%
Pays
BE
Échange UCB S.A. (UCB)
Catégorie
Healthcare
Revenus pour UCB S.A. (UCB)
Revenus en Jun 2026 TTM : $10.11B
Selon les derniers rapports financiers de UCB S.A., le chiffre d'affaires actuel de l'entreprise (TTM) est de $10.11B. En 2023, l'entreprise a réalisé un chiffre d'affaires de $5.81B une diminution par rapport à le chiffre d'affaires de l'année 2022, qui était de $5.92B. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour UCB S.A. de 2002 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $10.11B | 57.94% |
| 2024 | $6.40B | 10.26% |
| 2023 | $5.81B | -1.89% |
| 2022 | $5.92B | -9.92% |
| 2021 | $6.57B | 0.88% |
| 2020 | $6.51B | 18.13% |
| 2019 | $5.51B | 3.56% |
| 2018 | $5.32B | -0.85% |
| 2017 | $5.37B | 23.03% |
| 2016 | $4.36B | 3.68% |
| 2015 | $4.21B | 4.02% |
| 2014 | $4.05B | -6.09% |
| 2013 | $4.31B | -5.66% |
| 2012 | $4.57B | 8.68% |
| 2011 | $4.20B | -2.33% |
| 2010 | $4.30B | -3.70% |
| 2009 | $4.47B | -10.97% |
| 2008 | $5.02B | -5.32% |
| 2007 | $5.30B | 59.66% |
| 2006 | $3.32B | 20.02% |
| 2005 | $2.77B | -42.28% |
| 2004 | $4.79B | 14.36% |
| 2003 | $4.19B | -29.19% |
| 2002 | $5.92B | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $12.62B | 24.86% |
US
|
|
| $2.23B | -77.96% |
US
|
|
| $15.74B | 55.72% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | -40.45% |
NL
|
